American Journal of Cardiology
Volume 102, Issue 12 , Pages 1631-1643 , 15 December 2008

AJC Editor's Consensus: Psoriasis and Coronary Artery Disease

  • Vincent E. Friedewald, MD

      Affiliations

    • Assistant Editor, The American Journal of Cardiology, Clinical Professor, Department of Internal Medicine, The University of Texas Medical School at Houston, Houston, Texas, and Research Professor, University of Notre Dame, Notre Dame, Indiana
    • Corresponding Author InformationCorresponding author: Tel: 512-264-1611; fax: 512-264-7034
    • ,
  • Jennifer C. Cather, MD

      Affiliations

    • Co-Director, Graft vs. Host Clinic, and Co-Director, Cutaneous Lymphoma Clinic, Baylor University Medical Center, and Medical Director, Modern Dermatology, Dallas, Texas
    • ,
  • Joel M. Gelfand, MD, MSCE

      Affiliations

    • Medical Director, Clinical Studies Unit, Assistant Professor of Dermatology, and Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
    • ,
  • Kenneth B. Gordon, MD

      Affiliations

    • Associate Professor of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois
    • ,
  • Gary H. Gibbons, MD

      Affiliations

    • Director, Cardiovascular Research Institute, and Professor of Medicine, Morehouse School of Medicine, Atlanta, Georgia
    • ,
  • Scott M. Grundy, MD, PhD

      Affiliations

    • Professor of Medicine and Distinguished Chair in Human Nutrition, The University of Texas Southwestern Medical Center, Dallas, Texas
    • ,
  • Michael T. Jarratt, MD

      Affiliations

    • Clinical Associate Professor of Dermatology, Baylor College of Medicine, Houston, Texas, and Principal Investigator, DermResearch, Austin, Texas
    • ,
  • James G. Krueger, MD

      Affiliations

    • D. Martin Carter Professor in Clinical Investigation, The Rockefeller University, New York, New York
    • ,
  • Paul M. Ridker, MD

      Affiliations

    • Eugene Braunwald Professor of Medicine, Harvard Medical School, Boston, Massachusetts, and Director, Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • Neil Stone, MD

      Affiliations

    • Professor of Clinical Medicine, Feinberg School of Medicine, Northwestern University, and Medical Director, Center for Vascular Disease, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, Chicago, Illinois
    • ,
  • William C. Roberts, MD

      Affiliations

    • Editor-in-Chief, The American Journal of Cardiology and Baylor University Medical Center Proceedings, Dean, A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System, and Executive Director, Baylor Heart and Vascular Institute of Baylor University Medical Center, Dallas, Texas

References 

  1. National Psoriasis Foundation. About psoriasis: statistics. http://www.psoriasis.org/about/statsAssessed September 1, 2008
  2. Schon MP, Boehncke W-H. Psoriasis. N Engl J Med. 2005;352:1899–1912
  3. Griffiths CE, Barker JNW. Pathogensis and clinical features of psoriasis. Lancet. 2007;360:263–271
  4. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinant of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol. 2004;51:704–708
  5. Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol. 2006;54:685–704
  6. Van de Kerkhof PCM. The evolution of the psoriatic lesion. Br J Dermatol. 2007;157:4–15
  7. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rhuem Dis. 2005;64:ii30–ii36
  8. Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25:529–534
  9. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, et al National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58:1031–1042
  10. Gottieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatol Treat. 2008;19:5–21
  11. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, et al. T cells in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol. 1994;102:145–149
  12. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC, Haider AS, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128:1207–1211
  13. Menter A, Griffiths EM. Current and future management of psoriasis. Lancet. 2007;370:272–284
  14. Reed WB, Becker SW, Rhode R, Heiskell CL. Psoriasis and psoriatic arthritis (A clinicopathologic conference). Arch Dermatol. 1961;99:86
  15. McDonald CJ, Calabresi P. Complication on psoriasis. JAMA. 1973;224:629
  16. McDonald CJ, Calabresi P. Occlusive vascular disease in psoriatic patients. N Engl J Med. 1973;288:912
  17. Ena P, Madeddu P, Glorioso N, Cerimele D, Rappelli A. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol. 1985;40:199–205
  18. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32:982–986
  19. Lindegard B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica. 1986;172:298–304
  20. Krueger GG, Duvic M. Epidemiology of psoriasis: clinical issues. J Invest Dermatol. 1994;102:14S–18S
  21. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol. 1999;135:1490–1493
  22. Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004;19:225–230
  23. McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol. 1978;99:469–475
  24. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735–1741
  25. Kimball AB, Robinson D, Wu Y, Guzzo C, Yeilding N, Paramore C, et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001–2002. Dermatology. 2008;217:27–37
  26. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol. 2008;159:895–902
  27. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Sollner TM, Thaci D, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007;156:272–276
  28. Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. J Am Acad Dermatol. 2008;58:347–352
  29. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis. Arch Dermatol. 2007;143:1493–1499
  30. Wakke M, Thio HB, Prens EP, Sijbrands EJG, Neumann HAM. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis. 2007;190:1–9
  31. Dratelin CR, Martinez-Abundis E, Balcázar-Muñoz BR, Bustos-Saldaña R, González-Ortiz M. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol. 2003;48:882–885
  32. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta. 2001;303:33–39
  33. Neimann AI, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829–835
  34. Mallbris L, Ritchlin CT, Ståhle M. Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep. 2006;5:355–363
  35. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141:1527–1534
  36. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298:321–328
  37. Cohen AD, Gilutz H, Henkin Y, Zahger D, Shapiro J, Bonneh DY, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol. 2007;87:506–509
  38. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome (A cross-sectional study). Dermatology. 2008;216:152–155
  39. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157:68–73
  40. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003;112:1785–1788
  41. Panagiotakos DM, Pitsavos C, Yannakoulia M, Chrysohoou C, Stefanadis C. The implication of obesity and central fat on markers of chronic inflammation: the ATTICA study. Atherosclerosis. 2005;183:308–315
  42. Meigs JB, Wilson PWF, Nathan DM, D'Agostino RB, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio heart and Framingham offspring studies. Diabetes. 2003;52:2160–2167
  43. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB, Wilson PWF. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham offspring study. Circulation. 2004;110:380–385
  44. Olijhoek JK, Van der Graff Y, Banga J-D, Algra A, Rabelink TJ, Visseren FLJ. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J. 2004;25:342–348
  45. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol. 2005;288:H2031–H2041
  46. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al Diagnosis and management of the metabolic syndrome. Circulation. 2005;112:2735–2752
  47. Escalante A, Haas RW, del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis. Arch Intern Med. 2005;165:1624–1629
  48. Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Br J Dermatol. 2007;157:649–655
  49. Wannamethee G, Lowe GDO, Shaper AG, Rumley A, Lennon L, Whincup PH. Association between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J. 2005;26:1765–1773
  50. Fortes C, Mastroeni S, Leffondrè K, Sampogna F, Melchi F, Mazzotti E, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol. 2005;141:1580–1584
  51. Mallbris L, Granath F, Hamsten A, Ståhle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54:614–621
  52. Kural BV, Örem A, Cimsit G, Yandi YE, Calapoglu M. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta. 2003;328:71–82
  53. Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol. 2007;56:629–634
  54. Cohen AD, Dreiher J, Shapiro Y, Vidavsky L, Vardy DA, Davidovici B, et al. Psoriasis and diabetes: a population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2008;22:585–589
  55. Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, Badenhoop K, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol. 2007;157:1249–1251
  56. Kural BV, Örem A, Cimsit G, Uyda HA, Yandi YE, Alver A. Plasma homocysteine and its relationship with atherothrombotic markers in psoriatic patients. Clin Chim Acta. 2003;332:23–30
  57. Malebra M, Gisondi P, Radaeli A, Sala R, Calzavara Pinton PG, Girolomoni G. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol. 2006;155:1165–1169
  58. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases. Circulation. 1999;99:178–182
  59. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 1996;27:517–527
  60. Kaul S, Zadeh AA, Shah PK. Homocysteine hypothesis for atherothrombotic cardiovascular disease. J Am Coll Cardiol. 2006;48:914–923
  61. Wu Y, Mills D, Bala M. Psoriasis: cardiovascular risk factors and other disease comorbidities. J Drugs Dermatol. 2008;7:373–377
  62. Nasreen S, Ahmed I, Effendi S. Frequency and magnitude of anxiety and depression in patients with psoriasis vulgaris. J Coll Physicians Surg Pak. 2008;18:397–400
  63. Friedewald VE, Cather JC, Gordon KB, Kavanaugh A, Ridker PM, Roberts WC. The editor's roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol. 2008;101:1119–1126
  64. Vaccarino V, Johnson BD, Sheps DS, Reis SE, Kelsey SF, Bittner V, et al. Depression, inflammation, and incident cardiovascular disease in women with suspected coronary ischemia. J Am Coll Cardiol. 2007;50:2044–2050
  65. Carney RM, Blumenthal JA, Catellier D, Freedland KE, Berkman LF, Watkinds LL, et al. Depression as a risk factor for mortality after acute myocardial infarction. Am J Cardiol. 2003;92:1277–1281
  66. Barth J, Schumacher M, Hermann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med. 2004;66:802–813
  67. Wulsin LR, Singal BM. Do depressive symptoms increase the risk for the onset of coronary disease? (A systematic quantitative review). Psychosom Med. 2003;65:201–210
  68. Stewart JC, Janicki-Deverts D, Muldoon MF, Kamarck TW. Depressive symptoms moderate the influenza of hostility on serum interleukin-6 and C-reactive protein. Psychosom Med. 2008;70:197–204
  69. Michowitz Y, Goldstein E, Roth A, Afek A, Abashidze A, Gal YB, et al. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (trail) in atherosclerosis. J Am Coll Cardiol. 2005;45:1018–1024
  70. Zhang L, Peppel K, Sivashanmugam P, Orman ES, Brain L, Exum ST, et al. Expression of tumor necrosis factor receptor-1 in arterial wall cells promotes atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27:1087–1094
  71. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149–2153
  72. Piertzak AT, Zalewska A, Chodorwska G, Krasowska D, Michalak-Stoma A, Nockowski P, et al. Cytokines and anticytokines in psoriasis. Clin Chim Acta. 2008;394:7–21
  73. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126
  74. Spagnoli LG, Bonanno E, Sangiorgi G, Mauriello A. Role of inflammation in atherosclerosis. J Nucl Med. 2007;48:1800–1815
  75. Libby P. What have we learned about the biology of atherosclerosis? (The role of inflammation). Am J Cardiol. 2001;88(suppl):3J–6J
  76. Forrester JS. Prevention of plaque rupture: a new paradigm of therapy. Ann Intern Med. 2002;137:823–833
  77. Newby AC. Metalloproteinases and vulnerable atherosclerosis plaques. Trends Cardiovasc Med. 2007;17:253–258
  78. Shah PK. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol. 2003;41:15S–22S
  79. Friedewald VE, Ambrose JA, Roberts WC, Stone GW, Willerson JT. The editor's roundtable: the vulnerable plaque. Am J Cardiol. In press.
  80. Delves PJ, Roitt IM. The immune system. N Engl J Med. 2008;343:37–49
  81. Jiang H, Chess L. Regulation of immune responses by T cells. N Engl J Med. 2006;354:1166–1176
  82. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363–369
  83. Marnell L, Mold D, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005;117:104–111
  84. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilhas A, Teixeria F. The inflammatory response in mild and in severe psoriasis. Br J Dermatol. 2004;150:917–928
  85. Sergeant A, Markygerorgou A, Chan WC, Thorrat A, Burden D. C-reactive protein in psoriasis. Br J Dermatol. 2008;158:417–419
  86. Ohtsuka T. The relation between high-sensitivity C-reactive protein and maximum body mass index in patients with psoriasis. Br J Dermatol. 2008;158:1141–1143
  87. Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M. C-reactive protein and α2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venereol. 2004;18:180–183
  88. Beer FC, Hind CR, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarcation. Br Heart J. 1982;47:239–243
  89. Berk Bradford C, Weintraub WS, Alexander RW. Elevation of C-reactive protein in “active” coronary artery disease. Am J Cardiol. 1990;65:168–172
  90. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599–2610
  91. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  92. Sesso HD, Buring JE, Rafai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945–2951
  93. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007–2011
  94. Yeh ETH. CRP as a mediator of disease. Circulation. 2004;109:II-11–II-14
  95. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit?. Circulation. 2006;113:2128–2151
  96. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes. Circulation. 2006;113:72–75
  97. Inoue T, Komoda H, Nonaka M, Kameda M, Uchida T, Node K. Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int J Cardiol. 2008;124:319–325
  98. Natali A, L'Abbate , Ferrannini E. Erythrocyte sedimentation rate, coronary atherosclerosis, and cardiac mortality. Eur Heart J. 2003;24:639–648
  99. Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, et al Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med. 2006;144:249–256
  100. Buhlin K, Gustafsson A, Pockley G, Frostefård , Klinge B. Risk factors for cardiovascular disease in patients with periodontitis. Eur Heart J. 2003;24:2099–2107
  101. Chen Y-W, Umeda M, Nagasawa T, Takeuchi Y, Huang Y, Inoue Y, et al. Periodontitis may increase the risk of peripheral arterial disease. Eur J Vasc Endovasc Surg. 2008;35:153–158
  102. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2407–2415
  103. McMahon M, Hahn BH. Atherosclerosis and systemic lupus erythematosus- mechanistic basis of the association. Curr Opin Immunol. 2007;19:633–639
  104. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351:2611–2618
  105. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci. 2008;29:367–374
  106. Sahar S, Dwarakanath RS, Reddy A, Lanting L, Todorov I, Natarajan R. Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells. Circ Res. 2005;96:1064–1071
  107. Katariina K, Perola M, Terwilliger J, Kaprio J, Koskenvuo M, Syvänen A-C, et al. Evidence for involvement of the type 1 angiotensin II receptor locus in essential hypertension. Hypertension. 1999;33:844–849
  108. Pedrinelli R, Dell'Omo G, Di Bello V, Pellegrini G, Pucci L, Del Prato S, et al. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol. 2004;24:2414–2419
  109. Ferrario CM, Strawn WB. Role of renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;98:121–128
  110. Sironi L, Nobili E, Gianella A, Gelosa P, Tremoli E. Anti-inflammatory properties of drugs acting on the renin-angiotensin system. Drugs Today (Barc). 2005;41:609–622
  111. Schillaci G, Pirro M. C-reactive protein in hypertension significance and predictive value. Nutr Metab Cardiovasc Dis. 2006;16:500–508
  112. Lim HS, Lip GYH. Interleukin-15 in hypertension: further insights into inflammation and vascular disease. Am J Hypertens. 2005;18:1017–1018
  113. Hjeistuen A, Anderssen SA, Holme I, Seljeflot I, Klemdsal TO. Markers of inflammation are inversely related to physical activity and fitness in sedentary men with treated hypertension. Am J Hypertens. 2006;19:669–677
  114. Kampus P, Muda P, Kals J, Ristimäe T, Fischer K, Teesalu R, et al. The relationship between inflammation and arterial stiffness in patients with essential hypertension. Int J Cardiol. 2006;122:46–51
  115. Takase H, Nakazawa A, Yamashita S, Toriyama T, Sato K, Ueda R, et al. Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 3 diabetes mellitus who are receiving angiotensin II receptor blockers. Metab Clin Exp. 2007;56:559–564
  116. Karthikeyan VJ, Lip GYH. Alpha 1-microglobulin: a further insight to inflammation in hypertension?. Am J Hypertens. 2007;20:1022–1023
  117. Aznaouridis KA, Stefanadis CI. Inflammation and arterial function. Artery Res. 2007;1:32–38
  118. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension. 2005;46:1118–1122
  119. Setty AR, Curhan G, Chol HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women. Arch Intern Med. 2007;167:1670–1675
  120. Virdis A, Schiffrin EL. Vascular inflammation: a role in vascular disease in hypertension?. Curr Opin Nephrol Hypertens. 2003;12:181–187
  121. Engström G, Janzon L, Berglund O, Lind P, Stavenow L, Hedblad B, et al. Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol. 2002;22:2054–2058
  122. August P, Suthanthiran M. Transforming growth factor β signaling, vascular remodeling, and hypertension. N Engl J Med. 2006;354:2721–2723
  123. Ghanem FA, Movahed A. Inflammation in high blood pressure: a clinician prespective. J Am Soc Hypertens. 2007;1:113–119
  124. Lakoski SG, Herrington DM, Siscovick DM, Hulley SB. C-reactive protein concentration and incident hypertension in young adults. Arch Intern Med. 2006;166:345–349
  125. Guzlik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T-cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449–2460
  126. Brown NJ. Aldosterone and vascular inflammation. Hypertension. 2008;51:161–167
  127. Savoia C, Schiffrin EL. Reduction of c-reactive protein and the use of anti-hypertensives. Vasc Health Risk Manag. 2007;3:975–983
  128. Ruiz-Ortega M, Esteban V, Rupérez M, Sánchez-López E, Rodríquez-Vita J, Carvajal G, et al. Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens. 2006;15:159–166
  129. Ishibashi M, Hiasa K, Zhao Q, Inoue S, Ohtani K, Kitamoto S, et al Critical role of monocyte chemoattractant protein-a receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res. 2004;94:1203–1210
  130. Recinos A, Lejeune W, Sun H, Lee CY, Tieu BC, Lu , et al. Angiotensin II induces IL-6 expression and the Jak-stat2 pathway in aortic adventitia of LDL receptor-deficient mice. Atherosclerosis. 2007;194:125–133
  131. Libby P, Ridker PM. Inflammation and atherothrombosis. J Am Coll Cardiol. 2006;48:A33–A46
  132. Granger DN, Vowinkel T, Petnehazy T. Modulation of the inflammatory response in cardiovascular disease. Hypertension. 2004;43:924–931
  133. Prodanowich S, Ma F, Taylor R, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52:262–267
  134. Choi Hk, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173–1177
  135. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100:793–798
  136. White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007;99:91–98
  137. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2-inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081–1091
  138. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;353:1092–1102
  139. Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, et al Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;353:1071–1080
  140. Schönbeck U, Libby O. Inflammation, immunity, and HMG-CoA reductase inhibitors. Circulation. 2004;109:II-18–II-26
  141. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;26:1959–1965
  142. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109:II-2–II-10
  143. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels. JAMA. 2001;286:64–70
  144. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakova O, Ford I, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomized placebo controlled trial. Lancet. 2004;363:2015–2021
  145. Shirinsky IV, Shirinsky VS. Efficacy of simvastatin in plaque psoriasis: a pilot study. J Am Acad Dermatol. 2007;57:529–531
  146. Namazi MR. Statins: novel additions of the dermatologic arsenal?. Exp Dermatol. 2004;13:337–339
  147. Yu B-L, Zhao S-P. Anti-inflammatory effect is an important property of niacin on atherosclerosis beyond its lipid-altering effects. Med Hypotheses. 2007;69:90–94
  148. Kashyap ML, McGovern ME, Berra K, Guyton JR, Kwiterovich PO, Harper WL, et al Long-term study and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 2002;89:672–678
  149. Grundy SM, Vega GL, McGovern ME, Tullock BR, Kendall DM, Fitz-Patrick D, et al Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med. 2002;162:1568–1576
  150. Friedewald VE, Grundy S, Gotto AM, Haffner S, Denke MA, Hollander P, et al. The editor's roundtable: the metabolic syndrome. Am J Cardiol. 2007;99:382–389
  151. Ridker PM, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Khurmi NS, et al Baseline characteristics of participants in the Jupiter trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol. 2007;100:1659–1664
  152. Grundy SM, Cleeman JI, Mertz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  153. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252
  154. United States Department of Agriculture. Dietary guidelines for Americans 2005. http://www.health.gov/DIETARYGUIDELINES/dga2005/document/html/chapter9.htmAccessed October 28, 2008
  155. McKenney J. New perspective on the use of niacin in the treatment of lipid disorders. Arch Intern Med. 2004;164:697–705
  156. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol. 2007;99:22C–31C
  157. Cheng K, Wu TJ, Sturino C, Metters K, Gottesdiener K, Wright SD, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A. 2006;103:6682–6687
  158. Wolf R, Schiavo AL, Russo A, de Angelis F, Ruocco V. Effects of gemfibrozil on in vitro cultured normal human skin explants. Int J Dermatol. 1999;38:65–69
  159. Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol. 2007;25:606–615
  160. Kawamura AI, Ochiai T. Candesartan cilexetil induced pustular psoriasis. Eur J Dermatol. 2003;13:406–407
  161. Wakefield PE, Berger TG, James WD. Atenolol-induced pustular psoriasis. Arch Dermatol. 1990;126:968–969
  162. Coroas ASPS, de Olveira JGG, Magina S, Santos J, Pestana M, de Almeida MDV. Cyclosporine enhances salt sensitivity of body water composition as assessed by impedance among psoriatic patients with normal renal function. J Ren Nutr. 2004;14:226–232
  163. Rayyes OA, Wallmark A, Florén C-H. Cyclosporine inhibits catabolism of low-density lipoproteins in hepg2 cells by about 25%. Hepatology. 1996;24:613–619
  164. Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol. 1999;41:S7–S12
  165. Kwon HJ, Coté TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003;138:807–811
  166. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effects of anti-tumor necrosis factor therapy. Am J Med. 2004;116:305–311
  167. Bozhurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (Enbrel) in patients with advanced heart failure. Circulation. 2001;103:1044–1047
  168. Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, et al. Does tumor necrosis factor α inhibition promote or prevent heart failure in patients with rheumatoid arthritis?. Arthrit Rheum. 2008;58:667–677
  169. Danila MI, Patkar NM, Curtis JR, Saag KG, Teng GG. Biologics and heart failure in rheumatoid arthritis: are we any wiser?. Curr Opin Rheumatol. 2008;20:327–333
  170. Wolf R, Tamir A, Brenner S. Psoriasis related to angiotensin-converting enzyme inhibitors. Dermatologica. 1990;181:51–53

PII: S0002-9149(08)01870-5

doi: 10.1016/j.amjcard.2008.10.004

American Journal of Cardiology
Volume 102, Issue 12 , Pages 1631-1643 , 15 December 2008

Article Tools